Ponatinib-Related Vasospastic Angina

Area of Science:

• Oncology
• Cardiology
• Pharmacology

Background:

• Tyrosine kinase inhibitors (TKIs) are crucial for treating chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
• Cardiovascular and arteriothrombotic adverse events are known risks associated with TKI therapy.
• Vasospastic angina is a serious cardiovascular complication that can occur in patients receiving TKIs.

Purpose of the Study:

• To report three cases of vasospastic angina associated with Ponatinib, a specific TKI.
• To evaluate the efficacy of prophylactic treatment for Ponatinib-induced vasospastic angina.

Main Methods:

• Case series reporting three patients who developed vasospastic angina while on Ponatinib treatment.
• Review of medical records to assess the clinical presentation and management of the adverse events.
• Analysis of the effectiveness of prophylactic nitrates and calcium channel blockers.

Main Results:

• All three patients experienced vasospastic angina during Ponatinib therapy.
• Prophylactic administration of nitrates and/or calcium channel blockers was initiated.
• The prophylactic treatments were effective in preventing or managing the vasospastic angina episodes.

Conclusions:

• Ponatinib can induce vasospastic angina, a significant cardiovascular adverse event.
• Prophylactic use of nitrates and calcium channel blockers may be a beneficial strategy to mitigate this risk.
• Further research is warranted to understand the mechanisms and optimal management of TKI-associated vasospastic angina.